Skip to Main Content

Bristol-Myers Squibb and Celgene wrested biotech from its post-holiday malaise with a proposed $74 billion merger, a plan that has sweeping implications for the drug industry as it grapples with declining fortunes, pressure over pricing, and nagging questions about its scientific productivity.

Here are nine major takeaways from one of the biggest buyout in pharmaceutical history.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!